Pegcetacoplan

WITHDRAWN · PHASE3 · Delayed Graft Function, End Stage Renal Disease, Deceased Donor Kidney Transplant

The study was terminated following portfolio reprioritization and reallocation of resources to other development programs. The decision was not driven by safety or efficacy concerns arising from this trial.

Scientific benefit, asset-specific safety, ownership and licensing: Unknown without reviewed evidence.

Detailed evidence is available in the local Pro plan simulation.